Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.50 |
| ▸ | ATM | Q13315 | 1/20 | 0.50 |
| ▸ | ATR | Q13535 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.36 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | ACHE | P22303 | 1/20 | 0.33 |
| ▸ | TAS2R38 | P59533 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.31 |
| ▸ | BLM | P54132 | 1/20 | 0.31 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Ethane SCHEMBL5689604 | 1.00 | TSHR (0.50) | TSHRATMATRALDH1A1HSD17B10 | |
| Ethane SCHEMBL29145655 | 1.00 | TSHR (0.50) | TSHRATMATRALDH1A1HSD17B10 | |
| Ethane SCHEMBL4087796 | 0.95 | TSHR (0.46) | TSHRATMATRALDH1A1HSD17B10 | |
| Ethane SCHEMBL9345735 | 0.95 | TSHR (0.46) | TSHRATMATRALDH1A1HSD17B10 | |
| Ethane SCHEMBL11775118 | 0.95 | TSHR (0.46) | TSHRATMATRALDH1A1HSD17B10 | |
| Ethane SCHEMBL9748577 | 0.95 | TSHR (0.46) | TSHRATMATRALDH1A1HSD17B10 | |
| Ethane SCHEMBL1223967 | 0.95 | TSHR (0.46) | TSHRATMATRALDH1A1HSD17B10 | |
| Ethane SCHEMBL7082834 | 0.95 | TSHR (0.46) | TSHRATMATRALDH1A1HSD17B10 | |
| Ethane SCHEMBL11636383 | 0.95 | TSHR (0.46) | TSHRATMATRALDH1A1HSD17B10 | |
| Ethane SCHEMBL1879942 | 0.95 | TSHR (0.46) | TSHRATMATRALDH1A1HSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 240 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3787631-B1 | MODULATORS OF ORPHAN NUCLEAR RECEPTORS FOR NASH AND OTHER METABOLIC DISORDERS | UNIV EMORY (US) | 2025-09-10 | — | — | EP | claimed |
| EP-4255414-B1 | COMPOSITION CONTAINING RANITIDINE HAVING A LOW IRON CONTENT | OPELLA HEALTHCARE GROUP SAS (FR) | 2025-02-05 | — | — | EP | claimed |
| US-20240024278-A1 | COMPOSITION CONTAINING RANITIDINE HAVING A LOW IRON CONTENT | SANOFI CHIMIE (FR) | 2024-01-25 | — | — | US | claimed |
| CN-116887824-A | Compositions containing ranitidine with low iron content | 欧彼乐医疗集团公司 | 2023-10-13 | — | — | CN | claimed |
| EP-4255414-A1 | COMPOSITION CONTAINING RANITIDINE HAVING A LOW IRON CONTENT | Opella Healthcare Group SAS (FR) | 2023-10-11 | — | — | EP | claimed |
| EP-3976878-B1 | METHODS OF MAKING A DEFLECTION MEMBER | PROCTER & GAMBLE (US) | 2023-07-05 | — | — | EP | claimed |
| WO-2022117771-A1 | COMPOSITION CONTAINING RANITIDINE HAVING A LOW IRON CONTENT | OPELLA HEALTHCARE GROUP SAS (FR) | 2022-06-09 | — | — | WO | claimed |
| EP-3787631-A1 | MODULATORS OF ORPHAN NUCLEAR RECEPTORS FOR NASH AND OTHER METABOLIC DISORDERS | Emory University (US) | 2021-03-10 | — | — | EP | claimed |
| US-20210052603-A1 | MODULATORS OF ORPHAN NUCLEAR RECEPTORS FOR NASH AND OTHER METABOLIC DISORDERS | EMORY UNIVERSITY | 2021-02-25 | — | — | US | claimed |
| EP-1742993-B1 | RUBBER COMPOSITION AND TIRE COMPRISING SAME | MICHELIN & CIE (FR) | 2018-07-04 | — | — | EP | claimed |
| EP-1660078-A1 | USE OF INDOMETHACIN AND DERIVATIVES AS BROAD-SPECTRUM ANTIVIRAL DRUGS AND CORRESPONDING PHARMACEUTICAL COMPOSITIONS. | Università degli Studi di Roma " Tor Vergata" (IT) | 2006-05-31 | — | — | EP | claimed |
| JP-2006514917-A | — | — | 2006-05-18 | — | — | JP | claimed |
| EP-1581167-A2 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF PARKINSON'S DISEASE AND TARDIVE DYSKINESIAS | Alpha Research Group, LLC (US) | 2005-10-05 | — | — | EP | claimed |
| WO-2005013980-A1 | USE OF INDOMETHACIN AND DERIVATIVES AS BROAD-SPECTRUM ANTIVIRAL DRUGS AND CORRESPONDING PHARMACEUTICAL COMPOSITIONS. | UNIVERSITA' DEGLI STUDI DI ROMA 'TOR VERGATA' (IT) | 2005-02-17 | — | — | WO | claimed |
| US-20040229908-A1 | Compositions and methods for the treatment of Parkinson's disease and tardive dyskinesias | Greenlee, Winner and Sullivan, P.C. | 2004-11-18 | — | — | US | claimed |
| WO-2004004660-A2 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF PARKINSON’S DISEASE AND TARDIVE DYSKINESIAS | ALPHA RESEARCH GROUP, L.L.C. (US) | 2004-01-15 | — | — | WO | claimed |
| US-20020198231-A1 | Compositions and methods for the treatment of Parkinson's disease | Greenlee, Winner and Sullivan, P.C. | 2002-12-26 | — | — | US | claimed |
| WO-1997009976-A2 | METHOD OF REDUCING NEUROTOXIC INJURY WITH ZINC CHELATORS | WASHINGTON UNIVERSITY (CH) | 1997-03-20 | — | — | WO | claimed |
| EP-0152253-B1 | METHOD FOR THE DETERMINATION OF CERULOPLASMIN ACTIVITY IN A SAMPLE | Kyowa Medex Co. Ltd. (JP) | 1991-10-16 | — | — | EP | claimed |
| WO-1989002430-A1 | NEW CHOLINE COMPOUND, METHOD FOR ITS PREPARATION AND NEW DRUGS CONTAINING IT | LAFON PHARMA S.A. (CH) | 1989-03-23 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210052603-A1 | MODULATORS OF ORPHAN NUCLEAR RECEPTORS FOR NASH AND OTHER METABOLIC DISORDERS | RORA, RORB, RORC | TSHR 244/4885ATM 2774/4885ATR 3279/4885 |
| US-20240024278-A1 | COMPOSITION CONTAINING RANITIDINE HAVING A LOW IRON CONTENT | TFRC, HAMP, HRH2 | TSHR 2722/4885ATM 4882/4885ATR 4605/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.